NVA Puts Its Specialty and Emergency Leaders in Charge of the Whole Network

Two executives who built their careers running the specialty and emergency side of veterinary care now oversee the entire operation, general practice included. National Veterinary Associates named Leslie Storms its first company-wide chief operating officer and promoted Dr. Stacy Burdick into a newly created role setting medical strategy across all 1,300-plus hospitals in the network, unifying leadership across two businesses the company deliberately split apart three years ago.

NVA names Storms COO, Burdick company-wide CMO

Effective August 6, National Veterinary Associates named Leslie Storms chief operating officer, giving her operational authority across the roughly 1,300 general-practice, specialty, emergency, and equine hospitals the company operates across North America. Storms previously served as president of Ethos Veterinary Health, the specialty and emergency network of more than 140 hospitals that NVA carved out as a separately managed business in 2023.

Alongside her, Dr. Stacy Burdick, DVM, MBA, DACVIM, moves into a newly created chief medical officer role spanning general practice, specialty, and emergency medicine company-wide, a single seat that didn't exist before this appointment. Burdick was previously chief medical officer at Ethos, where she helped integrate four legacy specialty organizations into that 140-hospital network.

Both executives report into CEO John Bruno's leadership team. The release frames the moves as advancing "the next phase" of NVA's strategy and names no departures tied to either appointment.

Why specialty leadership now runs general practice

The operator signal here isn't the org chart, it's who filled it and what structure it undoes. In March 2023, NVA announced it was splitting into two separately managed businesses, general practice under the NVA brand and specialty/emergency under Ethos, with each reportedly eyeing its own initial public offering within two to three years. Giving one executive operational control and another sole medical authority over both businesses at once is a meaningful walk-back of that separation, whatever NVA's IPO plans have become since.

Both new company-wide roles also went to executives whose entire NVA track record sits inside Ethos, not the general-practice hospitals that make up the bulk of the network's 1,300 locations. Companies promote from the unit they most want to replicate. NVA just told the market, through its own personnel decisions, which side of the house it sees as the operating model for the rest.

There's a margin logic behind that choice. Specialty and emergency medicine runs materially higher margins than general practice, and referral capture, keeping a case inside the same corporate family instead of losing it to an independent specialty practice, is one of the more valuable levers a consolidator controls. A single chief medical officer spanning both segments is a structural precondition for standardizing referral protocols and measuring how much general-practice caseload actually converts into Ethos-side visits.

Scope is the cleanest way to size the move. Storms and Burdick each ran a roughly 140-hospital specialty network at Ethos. Their new roles cover NVA's full 1,300-plus hospital system, an operational footprint roughly nine times larger than what either previously managed. That's company-disclosed hospital-count data from the same release, not a modeled estimate, and it says more about the scale of the bet than either executive's title does.

It's also a data point for the broader private-equity veterinary consolidation trend. NVA is backed by JAB Consumer Partners, and unifying leadership after years of running two businesses separately is the kind of move that tends to surface once a roll-up's returns start depending on operating leverage rather than adding locations. The Underbite has tracked a similar dynamic on the distribution side, where the Covetrus-MWI merger drew a deeper FTC look partly over concentration concerns; the common thread across both is consolidators reaching for tighter internal coordination as the next lever once market share gets harder to buy.

One thing the release doesn't say: whether Burdick reports through Storms's new operating structure or directly to Bruno alongside her. That reporting line would show whether NVA is centralizing medicine underneath operations or keeping clinical strategy a parallel, co-equal function, a real difference in how much authority a single executive now holds over both what NVA's vets do and how the business runs.

Whether the separate-IPO plan survives this reorganization

The clearest open question is what happens to the IPO track NVA and Ethos each reportedly set out on in 2023. Unified operational and medical leadership across both businesses doesn't prove that plan is dead, but two companies preparing for independent public offerings don't typically converge their top operating and clinical roles into one person apiece. Any statement from NVA or JAB Consumer Partners about the status of those listings would be the clearest signal yet.

NVA's move is also worth tracking against the rest of the veterinary consolidation field. Mars-owned networks, Thrive Pet Healthcare, and other multi-brand roll-ups have historically kept general-practice and specialty medical leadership separate, mirroring the acquisition structure that built them. If unifying that function helps NVA move more cases internally, competitors have a template to copy.

Two vacancies are worth watching as well. Storms and Burdick's promotions leave the Ethos president and Ethos chief medical officer seats open, and who NVA names to backfill them, an internal promotion versus an outside hire, will say something about how deep its specialty-side bench actually runs. NVA does not report public earnings, so operators tracking the aftermath will be watching trade coverage and hospital-level referral trends rather than a quarterly filing for signs the bet is paying off.

Source: National Veterinary Associates via PR Newswire